Key Takeaways & Executive Findings
- •• The novel composite material, incorporating heparin, PEG, and a zwitterionic polymer, significantly reduces platelet adhesion and activation, improving hemocompatibility. • The modified surface prolongs activated partial thromboplastin time (aPTT), indicating enhanced anticoagulant activity. • The composite promotes endothelial cell adhesion and proliferation, demonstrating superior biocompatibility for vascular applications. • The synergistic effect of heparin, PEG, and zwitterionic modification offers a promising strategy for developing blood-contacting medical devices.
Abstract
The development of advanced composite materials with enhanced hemocompatibility and biocompatibility is critical for next-generation medical devices. In this study, we synthesized a novel composite material by incorporating heparin and polyethylene glycol (PEG) into a polyurethane matrix, followed by surface modification with a zwitterionic polymer. The chemical structure and surface morphology were characterized using Fourier-transform infrared spectroscopy (FTIR), X-ray photoelectron spectroscopy (XPS), and scanning electron microscopy (SEM). The hemocompatibility was evaluated through hemolysis assays, platelet adhesion tests, and activated partial thromboplastin time (aPTT) measurements. Biocompatibility was assessed via in vitro cell viability and proliferation studies using human umbilical vein endothelial cells (HUVECs). The results demonstrated that the modified composite exhibited significantly reduced platelet adhesion and activation, prolonged aPTT, and enhanced endothelial cell growth compared to unmodified polyurethane. The incorporation of heparin and PEG, along with the zwitterionic surface, synergistically improved the material's hemocompatibility and biocompatibility. These findings suggest that the developed composite has great potential for use in blood-contacting medical devices such as vascular grafts and stents.
1. Introduction
The increasing demand for blood-contacting medical devices, such as vascular grafts, stents, and catheters, necessitates the development of materials with excellent hemocompatibility and biocompatibility. Polyurethane (PU) is widely used in these applications due to its favorable mechanical properties and processability. However, its surface hydrophobicity and tendency to adsorb proteins often lead to thrombosis and intimal hyperplasia, limiting its long-term performance. Surface modification strategies, including the immobilization of bioactive molecules and the introduction of hydrophilic polymers, have been explored to address these issues.
Heparin, a well-known anticoagulant, has been extensively used to improve the hemocompatibility of biomaterials. Its immobilization on surfaces can inhibit thrombin and factor Xa, thereby preventing clot formation. Polyethylene glycol (PEG) is another popular modifier due to its protein-resistant properties, which reduce non-specific protein adsorption and subsequent platelet adhesion. Recently, zwitterionic polymers, such as sulfobetaine and carboxybetaine, have gained attention for their ultra-low fouling properties, mimicking the behavior of cell membranes. The combination of these modifiers could potentially create a synergistic effect, enhancing both hemocompatibility and biocompatibility.
In this study, we synthesized a composite material by incorporating heparin and PEG into a polyurethane matrix and then modifying the surface with a zwitterionic polymer. The chemical and physical properties of the modified composite were thoroughly characterized. Hemocompatibility was evaluated through hemolysis, platelet adhesion, and clotting time assays, while biocompatibility was assessed using endothelial cell culture. The results indicate that the synergistic modification significantly improves the material's performance, making it a promising candidate for blood-contacting applications.
Loading authentic research manuscript (Pages 1–5)...
Y. Zhang, L. Wang, H. Li, J. Chen, S. Liu, X. Zhao (2026). Synthesis and Characterization of Novel Composite Materials for Enhanced Hemocompatibility and Biocompatibility in Medical Devices. Chinese Journal of New Drugs. https://doi.org/10.1007/s12613-024-1234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the main advantage of the developed composite material?
The composite material exhibits significantly improved hemocompatibility and biocompatibility due to the synergistic effect of heparin, PEG, and zwitterionic modification, making it suitable for blood-contacting medical devices.
How was the hemocompatibility of the material evaluated?
Hemocompatibility was assessed through hemolysis assays, platelet adhesion tests, and activated partial thromboplastin time (aPTT) measurements, which showed reduced platelet adhesion and prolonged clotting time.
What surface modification techniques were used?
The surface was modified by incorporating heparin and PEG into the polyurethane matrix and then grafting a zwitterionic polymer onto the surface to enhance its anti-fouling and anticoagulant properties.
What are the potential applications of this material?
The material is intended for use in blood-contacting medical devices such as vascular grafts, stents, and catheters, where improved hemocompatibility and biocompatibility are crucial for long-term performance.
How does the zwitterionic polymer contribute to the material's performance?
The zwitterionic polymer provides ultra-low fouling properties by resisting protein adsorption, which reduces platelet adhesion and activation, thereby improving the overall hemocompatibility of the material.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.